Domagrozumab

Domagrozumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target GDF-8
Clinical data
ATC code none
Identifiers
CAS Number 1629605-31-7
ChemSpider none
Chemical and physical data
Formula C6366H9826N1690O2008S46
Molar mass 143.6 kDa

Domagrozumab (INN) is a humanized monoclonal antibody designed for the treatment of Duchenne muscular dystrophy.[1][2]

This drug was developed by Pfizer.

References

  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Domagrozumab, American Medical Association.
  2. World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
This article is issued from Wikipedia - version of the 11/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.